期刊文献+

耐甲氧西林金黄色葡萄球菌的耐药性研究 被引量:7

Resistance of Methicillin-resistant Staphylococcus Aureus
暂未订购
导出
摘要 监测金黄色葡萄球菌的耐药状况 ,为临床治疗耐甲氧西林金黄色葡萄球菌 (MRSA)的感染提供依据。采用试管双倍稀释法 (改良 )及纸片扩散法对 12 8株金黄色葡萄球菌进行药敏试验 ,并用 Nitrocefin纸片法测定其 β-内酰胺酶。 MRSA检出率 72 .6 5 % ,产 β-内酰胺酶 83.70 %。对青霉素 G、克林霉素、红霉素、头孢唑啉、庆大霉素、四环素的耐药率在 10 0 %~ 92 .47%之间 ,万古霉素、去甲万古霉素对所有菌株的抑菌率达 10 0 %。多数药物对甲氧西林敏感金黄色葡萄球菌 (MSSA)作用良好 ,头孢唑啉、利福平、亚胺培南和异帕米星的抑菌率均在 94.3%~ 10 0 %之间。MRSA对多数 β-内酰胺类、氟喹诺酮类及某些氨基糖苷类抗生素呈多重耐药性。万古霉素、去甲万古霉素对其显示最强的抗菌活性 ,利福平、壁霉素、异帕米星亦显示较强的抗菌活性 ,提示上述抗菌药物可用于 In order to control the nosocomial infections caused by methicillin resistant staphylococcus aureus (MRSA), the resistance of MRSA isolates from patients was investigated, the susceptibility to 24 antibacterial agents tested by using agar dilution test and Kirby Bauer respectively, and the β lactates deteted by using nitrocefin method. The results showed the detectable rate of MRSA was 72 65 % 83 7 % MRSA were positive for β lactamase. The resistance rate of PG, clindamycin, erythromycin. Cefazolin, gentamicin, tetracycline was from 92 24 % to 100 %. Vancomycin and norvancomycin could inhibit all isolates tested. Most of the drugs were active against methicillin sensitive staphylococcus. The inhibition rate of cefazolin, rifampin, imipenem and isepamicin was from 94 3 % to 100 % MRSA was multidrug resistance to most of β lactams fluoroquiolones and some aminoglycoside antibiotics. Vancomycin and norvancomycin possessed a strongest activity for MRSA, and rifampin, teicoplanin and isepamicin also revealed a stronger active against MRSA, suggesting all of them could be used to control MRSA infection.
出处 《同济医科大学学报》 CSCD 2000年第3期264-267,共4页 Acta Universitatis Medicinae Tongji
关键词 抗药性 金黄色葡萄球菌 Β-内酰胺酶类 抗生素 resistance, microorganism staphylococcus aureus β-lactamase
  • 相关文献

参考文献4

二级参考文献2

共引文献48

同被引文献18

  • 1祝勇梅 吴树荣.喹诺酮类抗菌药[A].见:王睿.临床抗菌治疗手册:第一版[C].北京:人民军医出版社,1994.169~179.
  • 2[1]Sahm DF, Washington JA Ⅱ. Antibacterial susceptibility tests: dilution methods[A]. Manual of clinical microbiology[M]. 6th ed. 1995. 1117.
  • 3[2]Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations[A]. Antibootics in Laboratory Medicine[M]. 4th ed. 1996. 330.
  • 4[6]Boger DL. Vancomycin, teicoplanin and ramoplanin: synthetic and mechanistic studies[J]. Med Res Rev, 2001, 21(5): 356-381.
  • 5[7]Wood MJ. Comparative safety of teicoplanin and vancomycin[J]. J Chemother, 2000, 12(Suppl5): 21-25.
  • 6[8]Morio A, Miyamoto H, Yamazaki A, et al. A case of primary lung cancer complicated with post-operative intractable pulmonary fistula[J]. Kyobu Geka, 2000, 53(13): 1144-1147.
  • 7[1]Sahm DF、 Washington Ⅱ JA. Antibacterial susceptibility tests : dilution methods . Manual of clinical microbiology, 6th ed. 1995: 1117.
  • 8[2]George M. Eliopoulos、Robert C. Moellering, JR. Antimicrobial Combinations. Antibootics in Laboratory Medicine, 4th ed, 1996:330
  • 9[6]Boger DL. Vancomycin, teicoplanin and ramoplanin: synthetic and mechanistic studies. Med Res Rev, 2001, 21: 356.
  • 10[7]Wood MJ. Comparative safety of teicoplanin and van comycin. J Chemother, 2000, 12 (Suppl5): 21.

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部